This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Heinmöller, P. Articles by Rüschoff, J. Search for Related Content PubMed PubMed Citation Articles by Heinmöller, P. Articles by Rüschoff, J.

HER2 Status in Non-Small Cell Lung Cancer

Results from Patient Screening for Enrollment to a Phase II Study of Herceptin

Institut für Pathologie, Klinikum Kassel, D-34125 Kassel, Germany [P. H., C. G., K. B., C. S., J. R.]; Hoffmann La-Roche Ltd., Penzberg, Germany [G. M.]; and Hoffmann La-Roche Ltd., Basel, Switzerland [M. P.]

Purpose: For the first time a large number (563) of non-small cell lung cancer (NSCLC) samples was used to compare three different technologies for the assessment of HER2 status. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were used for tumor tissue samples, and ELISA for serum samples. The results were compared with other tumor entities, mainly breast.

Experimental Design: Samples (563) from patients suffering from primary advanced or metastatic NSCLC were evaluated.

Results: HER2 overexpression was demonstrated using IHC in 20% (83 of 410) of the specimens, whereas 2% (7 of 378) were positive by FISH and 6% (31 of 511) showed elevated serum HER2 levels (>15 ng/ml) by ELISA. Sixty-six specimens were positive by IHC only and 13 by ELISA only, whereas none of the specimens was positive only by FISH. Concordance between all of the techniques was seen for only 3 specimens. Of 7 IHC 3+ specimens, 4 showed gene amplification by FISH, and 3 were positive by ELISA (>15 ng/ml), whereas of 76 IHC 2+ cases only 2 were amplified by FISH, and 4 were positive by ELISA. HER2 positivity by at least one of the three techniques was most common in adenocarcinomas, at 29% (42 of 143).

Conclusion: Gene amplification and HER2 protein overexpression at the 3+ level appear to be uncommon in NSCLC. The concordance between FISH and IHC 3+ disease was good in this study, in addition, ELISA would have detected several patients without IHC/FISH-positive disease.